symbol,statement_type,period_end,line_item,value
AUROPHARMA.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,-622966499.057326
AUROPHARMA.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.324698
AUROPHARMA.NS,income,2025-03-31 00:00:00,Normalized EBITDA,71729500000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Total Unusual Items,-1918600000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-1918600000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,37895100000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,16494200000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,130262400000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,EBITDA,69810900000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,EBIT,53316700000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Net Interest Income,-4572400000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Interest Expense,4572400000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Interest Income,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Normalized Income,39190733500.94267
AUROPHARMA.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,37895100000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Total Expenses,264221100000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Diluted Average Shares,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Basic Average Shares,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Diluted EPS,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Basic EPS,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,37895100000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,37895100000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Net Income,37895100000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Minority Interests,23200000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,34835700000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,32917100000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Tax Provision,15827200000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Pretax Income,48744300000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,6218500000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Special Income Charges,-1918600000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Other Special Charges,1918600000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Write Off,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Impairment Of Capital Assets,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Restructuring And Mergern Acquisition,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-4572400000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,4572400000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Operating Income,49560200000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Operating Expense,133958700000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Other Operating Expenses,76164300000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,16494200000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Amortization,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,16494200000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Research And Development,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Selling General And Administration,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
AUROPHARMA.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
AUROPHARMA.NS,income,2025-03-31 00:00:00,Gross Profit,183518900000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Cost Of Revenue,130262400000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Total Revenue,313781300000.0
AUROPHARMA.NS,income,2025-03-31 00:00:00,Operating Revenue,313781300000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.264886
AUROPHARMA.NS,income,2024-03-31 00:00:00,Normalized EBITDA,63832200000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Total Unusual Items,0.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,31729700000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,15216600000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,126029000000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,EBITDA,63832200000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,EBIT,48615600000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Net Interest Income,-2897100000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Interest Expense,2897100000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Interest Income,2857600000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Normalized Income,31729700000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,31729700000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Total Expenses,243831600000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,1204200000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Diluted Average Shares,585851182.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Basic Average Shares,585851182.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Diluted EPS,54.16
AUROPHARMA.NS,income,2024-03-31 00:00:00,Basic EPS,54.16
AUROPHARMA.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,31729700000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,31729700000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Net Income,31729700000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Minority Interests,40000000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,31689700000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,33608300000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Tax Provision,12110200000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Pretax Income,45718500000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,5186000000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Special Income Charges,0.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Other Special Charges,-1540900000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Write Off,2298100000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Impairment Of Capital Assets,623700000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Restructuring And Mergern Acquisition,986600000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-2897100000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,216200000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,2897100000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,2857600000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Operating Income,43213400000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Operating Expense,117802600000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Other Operating Expenses,66330300000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,15216600000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Amortization,5737700000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,15216600000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Research And Development,756300000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Selling General And Administration,25024100000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,16847200000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,General And Administrative Expense,8176900000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,1204200000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Gross Profit,161016000000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Cost Of Revenue,126029000000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Total Revenue,287045000000.0
AUROPHARMA.NS,income,2024-03-31 00:00:00,Operating Revenue,287045000000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,-28123330.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.2621
AUROPHARMA.NS,income,2023-03-31 00:00:00,Normalized EBITDA,39967600000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Total Unusual Items,-107300000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-107300000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,19275000000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,12445800000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,118997000000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,EBITDA,39860300000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,EBIT,27414500000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Net Interest Income,54100000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Interest Expense,1289500000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Interest Income,1458900000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Normalized Income,19354176670.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,19275000000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Total Expenses,220795300000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,1337600000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Diluted Average Shares,585938609.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Basic Average Shares,585938609.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Diluted EPS,32.9
AUROPHARMA.NS,income,2023-03-31 00:00:00,Basic EPS,32.9
AUROPHARMA.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,19275000000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,19275000000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Net Income,19275000000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Minority Interests,-1500000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,19276500000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,19276500000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Tax Provision,6848500000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Pretax Income,26125000000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,1288400000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Special Income Charges,-107300000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Other Special Charges,-132300000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Write Off,0.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Impairment Of Capital Assets,239600000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Restructuring And Mergern Acquisition,0.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,54100000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,115300000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,1289500000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,1458900000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Operating Income,25376000000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Operating Expense,101798300000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Other Operating Expenses,31288000000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,12445800000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Amortization,4112900000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,8332900000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Research And Development,395100000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Selling General And Administration,23481700000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,16857600000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,General And Administrative Expense,6624100000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,1337600000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Gross Profit,127174300000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Cost Of Revenue,118997000000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Total Revenue,246171300000.0
AUROPHARMA.NS,income,2023-03-31 00:00:00,Operating Revenue,246171300000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,-129690360.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.1116
AUROPHARMA.NS,income,2022-03-31 00:00:00,Normalized EBITDA,46523100000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Total Unusual Items,-1162100000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-1162100000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,26481500000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,11265200000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,108151800000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,EBITDA,45361000000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,EBIT,34095800000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Net Interest Income,-170400000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Interest Expense,368400000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Interest Income,316000000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Normalized Income,27513909640.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,26481500000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Total Expenses,200662800000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,1241900000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Diluted Average Shares,585938609.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Basic Average Shares,585938609.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Diluted EPS,45.19
AUROPHARMA.NS,income,2022-03-31 00:00:00,Basic EPS,45.19
AUROPHARMA.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,26481500000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,26481500000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Net Income,26481500000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Minority Interests,10400000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,26471100000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,26471100000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Tax Provision,7256300000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Pretax Income,33727400000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,1345600000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Special Income Charges,-1162100000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Other Special Charges,-760100000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Write Off,-22300000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Impairment Of Capital Assets,1922200000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Restructuring And Mergern Acquisition,
AUROPHARMA.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,-170400000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,118000000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,368400000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,316000000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Operating Income,33002700000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Operating Expense,92511000000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Other Operating Expenses,23949700000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,11265200000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Amortization,3286600000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,7978600000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Research And Development,652400000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Selling General And Administration,21770200000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,14966700000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,General And Administrative Expense,6803500000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,1241900000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Gross Profit,125513700000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Cost Of Revenue,108151800000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Total Revenue,233665500000.0
AUROPHARMA.NS,income,2022-03-31 00:00:00,Operating Revenue,233665500000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Total Unusual Items,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
AUROPHARMA.NS,income,2021-03-31 00:00:00,EBITDA,
AUROPHARMA.NS,income,2021-03-31 00:00:00,EBIT,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Net Interest Income,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Interest Expense,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Interest Income,223700000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Normalized Income,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Total Expenses,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,1225400000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Diluted Average Shares,585938609.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Basic Average Shares,585938609.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Diluted EPS,91.05
AUROPHARMA.NS,income,2021-03-31 00:00:00,Basic EPS,91.05
AUROPHARMA.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Net Income,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Minority Interests,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Tax Provision,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Pretax Income,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Special Income Charges,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Other Special Charges,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Write Off,281600000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Impairment Of Capital Assets,0.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Restructuring And Mergern Acquisition,-1528500000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,149200000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,223700000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Operating Income,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Operating Expense,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Amortization,2537800000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Research And Development,688100000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Selling General And Administration,24297200000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,15641700000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,General And Administrative Expense,8655500000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,1225400000.0
AUROPHARMA.NS,income,2021-03-31 00:00:00,Gross Profit,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Total Revenue,
AUROPHARMA.NS,income,2021-03-31 00:00:00,Operating Revenue,
